378 related articles for article (PubMed ID: 23958373)
1. Ibrutinib and novel BTK inhibitors in clinical development.
Akinleye A; Chen Y; Mukhi N; Song Y; Liu D
J Hematol Oncol; 2013 Aug; 6():59. PubMed ID: 23958373
[TBL] [Abstract][Full Text] [Related]
2. Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.
Aalipour A; Advani RH
Br J Haematol; 2013 Nov; 163(4):436-43. PubMed ID: 24111579
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.
Davids MS; Brown JR
Future Oncol; 2014 May; 10(6):957-67. PubMed ID: 24941982
[TBL] [Abstract][Full Text] [Related]
4. Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Gozzetti A; Candi V; Brambilla CZ; Papini G; Fabbri A; Bocchia M
Anticancer Agents Med Chem; 2017; 17(8):1040-1045. PubMed ID: 27697038
[TBL] [Abstract][Full Text] [Related]
5. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
6. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma.
Ding N; Li X; Shi Y; Ping L; Wu L; Fu K; Feng L; Zheng X; Song Y; Pan Z; Zhu J
Oncotarget; 2015 Jun; 6(17):15122-36. PubMed ID: 25944695
[TBL] [Abstract][Full Text] [Related]
7. Bruton's TK inhibitors: structural insights and evolution of clinical candidates.
Xing L; Huang A
Future Med Chem; 2014 Apr; 6(6):675-95. PubMed ID: 24895895
[TBL] [Abstract][Full Text] [Related]
8. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
Honigberg LA; Smith AM; Sirisawad M; Verner E; Loury D; Chang B; Li S; Pan Z; Thamm DH; Miller RA; Buggy JJ
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13075-80. PubMed ID: 20615965
[TBL] [Abstract][Full Text] [Related]
9. Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.
Liu L; Shi B; Wang X; Xiang H
Future Med Chem; 2018 Feb; 10(3):343-356. PubMed ID: 29347836
[TBL] [Abstract][Full Text] [Related]
10. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
Burger JA; Buggy JJ
Leuk Lymphoma; 2013 Nov; 54(11):2385-91. PubMed ID: 23425038
[TBL] [Abstract][Full Text] [Related]
11. Strategies for overcoming resistance to Bruton's tyrosine kinase inhibitor zanubrutinib.
Dostálová H; Kryštof V
Hematol Oncol; 2024 Jul; 42(4):e3294. PubMed ID: 38847437
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib and indolent B-cell lymphomas.
Akinleye A; Furqan M; Adekunle O
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):253-60. PubMed ID: 24445187
[TBL] [Abstract][Full Text] [Related]
13. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
Woyach JA; Furman RR; Liu TM; Ozer HG; Zapatka M; Ruppert AS; Xue L; Li DH; Steggerda SM; Versele M; Dave SS; Zhang J; Yilmaz AS; Jaglowski SM; Blum KA; Lozanski A; Lozanski G; James DF; Barrientos JC; Lichter P; Stilgenbauer S; Buggy JJ; Chang BY; Johnson AJ; Byrd JC
N Engl J Med; 2014 Jun; 370(24):2286-94. PubMed ID: 24869598
[TBL] [Abstract][Full Text] [Related]
14. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.
Rushworth SA; Murray MY; Zaitseva L; Bowles KM; MacEwan DJ
Blood; 2014 Feb; 123(8):1229-38. PubMed ID: 24307721
[TBL] [Abstract][Full Text] [Related]
15. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
[TBL] [Abstract][Full Text] [Related]
16. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
17. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
[TBL] [Abstract][Full Text] [Related]
18. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
[TBL] [Abstract][Full Text] [Related]
19. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
Wang Y; Zhang LL; Champlin RE; Wang ML
Clin Pharmacol Ther; 2015 May; 97(5):455-68. PubMed ID: 25669675
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
